Rural Health
Resources by Topic: Illicit drug use
Reported Rural Drug Overdoses Decline 40 Percent in One Year (Pennsylvania)
Compares rates of drug overdoses in 2023 and 2024 in rural and urban areas of Pennsylvania. Features statistics on reported drug overdose rates per 100,000 during these years, percent of rural and urban residents receiving naloxone in 2023 and 2024, demographic information on rural overdose victims, and a county-level map showing percent change in reported overdoses by county.
Date: 05/2025
Sponsoring organization: Center for Rural Pennsylvania
view details
Compares rates of drug overdoses in 2023 and 2024 in rural and urban areas of Pennsylvania. Features statistics on reported drug overdose rates per 100,000 during these years, percent of rural and urban residents receiving naloxone in 2023 and 2024, demographic information on rural overdose victims, and a county-level map showing percent change in reported overdoses by county.
Date: 05/2025
Sponsoring organization: Center for Rural Pennsylvania
view details
Rural Access to Certified Community Behavioral Health Clinics (CCBHCs)
Examines access to, and services offered by, Certified Community Behavioral Health Clinics (CCBHCs) in rural and urban communities. Also compares services at CCBHCs with those offered at other mental health clinics. Features state-level maps showing CCBHC counts by state, and statistics on services counts in CCBHCs and other mental health facilities, with breakdowns by urban and rural areas.
Author(s): Aaron P. Smith, Jeffrey Talbert
Date: 05/2025
Sponsoring organization: Rural and Underserved Health Research Center
view details
Examines access to, and services offered by, Certified Community Behavioral Health Clinics (CCBHCs) in rural and urban communities. Also compares services at CCBHCs with those offered at other mental health clinics. Features state-level maps showing CCBHC counts by state, and statistics on services counts in CCBHCs and other mental health facilities, with breakdowns by urban and rural areas.
Author(s): Aaron P. Smith, Jeffrey Talbert
Date: 05/2025
Sponsoring organization: Rural and Underserved Health Research Center
view details
Impact of Recent Methamphetamine Use on Treatment Outcomes Among Individuals Initiating Medications for Opioid Use Disorders in Rural Treatment Settings: A 1-Year Retrospective Cohort Study
Explores the predictive role that methamphetamine urinalysis (UA) results in rural MOUD treatment intake has on methamphetamine and opioid use over time. Discusses the rise of co-use of opioids and methamphetamine and explores indicators for clinicians providing MOUD treatment.
Author(s): Leslie A Kenefick, Lisa Khairy, Luke Hall, et al.
Citation: Rural and Remote Health, 25(2), 9536
Date: 04/2025
view details
Explores the predictive role that methamphetamine urinalysis (UA) results in rural MOUD treatment intake has on methamphetamine and opioid use over time. Discusses the rise of co-use of opioids and methamphetamine and explores indicators for clinicians providing MOUD treatment.
Author(s): Leslie A Kenefick, Lisa Khairy, Luke Hall, et al.
Citation: Rural and Remote Health, 25(2), 9536
Date: 04/2025
view details
Different Forms of Stigma and Rural Primary Care Professionals' Willingness to Prescribe Buprenorphine
Presents a study exploring the different types of stigma affecting buprenorphine and other medications for opioid use disorder (MOUD) prescribing rates in rural primary care settings. Details perceived stigmas around MOUD by providers, such as the fear of being harmed by patients, fear of their professional image being harmed, and the fear of the medications harming their patients.
Author(s): Berkeley Franz, Lindsay Y. Dhanani, Sean Bogart, et al.
Citation: Journal of Substance Use & Addiction Treatment, 171, 209633
Date: 04/2025
view details
Presents a study exploring the different types of stigma affecting buprenorphine and other medications for opioid use disorder (MOUD) prescribing rates in rural primary care settings. Details perceived stigmas around MOUD by providers, such as the fear of being harmed by patients, fear of their professional image being harmed, and the fear of the medications harming their patients.
Author(s): Berkeley Franz, Lindsay Y. Dhanani, Sean Bogart, et al.
Citation: Journal of Substance Use & Addiction Treatment, 171, 209633
Date: 04/2025
view details
Barriers and Facilitators to Scaling up Medications for Opioid Use Disorder in Kentucky: Qualitative Perspectives of Treatment Organization Staff
Examines perspectives from substance use treatment program staff related to the barriers and facilitators of medications for opioid use disorder (MOUD) utilization. Provides qualitative feedback data from agency staff in Kentucky and discusses organizational, patient, and community factors that impact MOUD utilization. Includes perspectives from rural areas.
Author(s): Hannah K. Knudsen, Shaquita Andrews-Higgins, Sandra Back-Haddix, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 20, 15
Date: 04/2025
view details
Examines perspectives from substance use treatment program staff related to the barriers and facilitators of medications for opioid use disorder (MOUD) utilization. Provides qualitative feedback data from agency staff in Kentucky and discusses organizational, patient, and community factors that impact MOUD utilization. Includes perspectives from rural areas.
Author(s): Hannah K. Knudsen, Shaquita Andrews-Higgins, Sandra Back-Haddix, et al.
Citation: Substance Abuse Treatment, Prevention, and Policy, 20, 15
Date: 04/2025
view details
Medicare Beneficiary Receipt of Methadone by Drive Time to Opioid Treatment Programs
Examines availability of methadone at opioid treatment programs for Medicare beneficiaries who have been diagnosed with an opioid use disorder. Utilizes data from 640,706 Medicare beneficiaries and analyzes their respective drive time to a treatment facility as well as receipt of methadone treatment. Includes U.S. map showing locations of opioid treatment programs and rural versus urban comparisons of patient drive times.
Author(s): Jonathan Cantor, Helin G. Hernandez, Aaron Kofner, et al.
Citation: JAMA Network Open, 8(4)
Date: 04/2025
view details
Examines availability of methadone at opioid treatment programs for Medicare beneficiaries who have been diagnosed with an opioid use disorder. Utilizes data from 640,706 Medicare beneficiaries and analyzes their respective drive time to a treatment facility as well as receipt of methadone treatment. Includes U.S. map showing locations of opioid treatment programs and rural versus urban comparisons of patient drive times.
Author(s): Jonathan Cantor, Helin G. Hernandez, Aaron Kofner, et al.
Citation: JAMA Network Open, 8(4)
Date: 04/2025
view details
Opioid Stewardship Programs in Rural Arizona
Provides an overview of Opioid Stewardship Programs (OSPs), and discusses OSP implementation and knowledge in Arizona from a survey of 39 Arizona rural hospital leaders and professionals. Includes an infographic on the results of the OSP survey and links to OSP training resources.
Author(s): Bridget S. Murphy
Date: 04/2025
Sponsoring organization: Arizona Center for Rural Health
view details
Provides an overview of Opioid Stewardship Programs (OSPs), and discusses OSP implementation and knowledge in Arizona from a survey of 39 Arizona rural hospital leaders and professionals. Includes an infographic on the results of the OSP survey and links to OSP training resources.
Author(s): Bridget S. Murphy
Date: 04/2025
Sponsoring organization: Arizona Center for Rural Health
view details
Controlled Substance Prescribing Patterns Among Fatal Overdose Decedents with an Opioid, Stimulant, or Both Contributing to Death — Pennsylvania, 2017–2022
Reports on deaths involving opioids without stimulants, deaths involving stimulants without opioids, and deaths involving both opioids and stimulants in Pennsylvania between 2017 and 2022. Includes data for rural and urban areas. Discusses the role of opioid prescribing on overdose deaths.
Author(s): Stephanie Hayden, Stanley M. Murzynski, Ashley Bolton, Carrie Thomas Goetz
Citation: MMWR (Morbidity and Mortality Weekly Report), 74(12), 205-209
Date: 04/2025
Sponsoring organization: Centers for Disease Control and Prevention
view details
Reports on deaths involving opioids without stimulants, deaths involving stimulants without opioids, and deaths involving both opioids and stimulants in Pennsylvania between 2017 and 2022. Includes data for rural and urban areas. Discusses the role of opioid prescribing on overdose deaths.
Author(s): Stephanie Hayden, Stanley M. Murzynski, Ashley Bolton, Carrie Thomas Goetz
Citation: MMWR (Morbidity and Mortality Weekly Report), 74(12), 205-209
Date: 04/2025
Sponsoring organization: Centers for Disease Control and Prevention
view details
The Rural and Urban Supply of Clinicians With a DEA Waiver to Prescribe Buprenorphine in 2022 Prior to the Elimination of the Waiver Requirement
Report explores the differences in rates of clinicians with DEA waivers to prescribe buprenorphine in 2022 in rural versus urban counties. Highlights the rural gaps in access to buprenorphine to treat opioid use disorder prior to the elimination of the DEA waiver requirement in 2023. Provides rural, urban, and regional comparisons.
Date: 04/2025
Sponsoring organization: WWAMI Rural Health Research Center
view details
Report explores the differences in rates of clinicians with DEA waivers to prescribe buprenorphine in 2022 in rural versus urban counties. Highlights the rural gaps in access to buprenorphine to treat opioid use disorder prior to the elimination of the DEA waiver requirement in 2023. Provides rural, urban, and regional comparisons.
Date: 04/2025
Sponsoring organization: WWAMI Rural Health Research Center
view details
Delivering Medications for Opioid Use Disorder in Primary Care: Environmental Scan
Report provides a literature review and interviews with key informants to outline the opioid use disorder (OUD) treatment environment and make policy recommendations. Discusses how changes to regulations have affected access to medications for opioid use disorder (MOUD), how the opioid use environment has changed, and what models and evidence-based tools exist to facilitate OUD treatment, among other issues.
Author(s): Collette Sosnowy, Danielle Durant, Garrett Moran, et al.
Date: 03/2025
Sponsoring organization: Agency for Healthcare Research and Quality
view details
Report provides a literature review and interviews with key informants to outline the opioid use disorder (OUD) treatment environment and make policy recommendations. Discusses how changes to regulations have affected access to medications for opioid use disorder (MOUD), how the opioid use environment has changed, and what models and evidence-based tools exist to facilitate OUD treatment, among other issues.
Author(s): Collette Sosnowy, Danielle Durant, Garrett Moran, et al.
Date: 03/2025
Sponsoring organization: Agency for Healthcare Research and Quality
view details